ClinicalTrials.Veeva

Menu
I

InSite Clinical Research | DeSoto, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KarXT
Buprenorphine
BHV-7000
Troriluzole
LY03010
Daridorexant
Brexpiprazole
SPN-810
Risperidone
Iclepertin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 90 total trials

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (APPROACH)

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in part...

Enrolling
Major Depressive Disorder
Behavioral: Psychological Support
Drug: CYB003

The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective sero...

Active, not recruiting
Anhedonia
Depressive Disorder, Major
Other: Placebo
Drug: Aticaprant

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmuco...

Enrolling
Treatment Resistant Depression
Drug: VLS-01-BU Placebo
Drug: VLS-01-203 BU

The primary purpose of this trial is to evaluate the safety and tolerability of centanafadine QD XR in pediatric subjects with ADHD.

Active, not recruiting
Attention Deficit/Hyperactivity Disorder
Drug: Centanafadine Hydrochloride

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.

Invitation-only
Bipolar Disorder
Drug: BHV-7000

This is a Phase 2 study randomized, quadruple masked, multi-center study , with a Open Label Extension, designed to investigate the efficacy and safe...

Active, not recruiting
Treatment Resistant Depression
Drug: BPL-003

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The mai...

Enrolling
Major Depressive Disorder
Drug: Zelquistinel

The current study will evaluate the pharmacokinetics, safety, and tolerability of INDV-6001 following multiple doses in participants with opioid use...

Enrolling
Moderate to Severe Opioid Use Disorder
Drug: Sublocade
Drug: INDV-6001

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate t...

Enrolling
Opioid Use Disorder
Drug: INDV-2000
Other: Placebo

This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of...

Enrolling
Major Depressive Disorder
Drug: Centanafadine
Drug: Placebo

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive d...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

Trial sponsors

Indivior logo
Pfizer logo
Otsuka logo
Boehringer Ingelheim logo
Biohaven logo
Biohaven logo
Karuna Therapeutics logo
Sumitomo Pharma logo
Bristol-Myers Squibb (BMS) logo
Idorsia Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems